Cue Biopharma, Inc.

CUENASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
27.01 USD
↗ 0.36 (1.35%)AT CLOSE (11:59 AM EDT)
27.55
↗ 0.54 (2.00%)
POST MARKET (AS OF 07:34 PM EDT)
Post Market
AS OF 07:34 PM EDT
27.55
↗ 0.54 (2.00%)
🔴Market: CLOSED

CUE is currently priced at $27.02. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, CUE trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Aug 6, 2026.

Open?$26.69
High?$28.46
Low?$26.54
Prev. Close?$26.65
Volume?151.1K
Avg. Volume?155.4K
VWAP?$27.54
Rel. Volume?0.97x
Bid / Ask
Bid?$22.68 × 100
Ask?$32.13 × 100
Spread?$9.45
Midpoint?$27.41
Valuation & Ratios
Market Cap?111.9M
Shares Out?4.2M
Float?3.5M
Float %?87.6%
P/E Ratio?N/A
P/B Ratio?5.18
EPS?-$4.65
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
29
Market Cap
111.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.cuebiopharma.com
Listed
2018-01-02
Address
40 GUEST STREET
BOSTON, MA 02135
Phone: 617-949-2680
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
77
Short Sent.?
46
Piotroski F-Score?2/9Weak
Altman Z-Score?-9.99Distress
Confidence?48%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?8.69%Elevated
Short Interest?307.9K
Days to Cover?2.2
Free Float3.5M
Avg Daily Volume138.7K
Settlement Date2026-07-15
Financial Health
Current Ratio?3.57Strong
Quick Ratio?3.57Strong
Cash Ratio?2.22Strong
Debt/Equity?0.05Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
36
5.18FAIR▾
P/S?
Peers
100
S&P
45
3.42FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.3CHEAP▾
EV/Sales?
Peers
100
S&P
61
2.95CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-90.4%WEAK▾
ROA?
S&P
3
-63.2%WEAK▾
Cash Flow & Enterprise
FCF?$-24605000
Enterprise Value?$96.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist